Viscosupplementation for the treatment of osteoarthritis of the knee

Bellamy, N., Campbell, J., Robinson, V., Gee, T., Bourne, R. and Wells, G. (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. The Cochrane database of systematic reviews, 2: .

Author Bellamy, N.
Campbell, J.
Robinson, V.
Gee, T.
Bourne, R.
Wells, G.
Title Viscosupplementation for the treatment of osteoarthritis of the knee
Journal name The Cochrane database of systematic reviews   Check publisher's open access policy
ISSN 1469-493X
Publication date 2006-01-01
Sub-type Article (original research)
Open Access Status Not yet assessed
Issue 2
Language eng
Subject 2736 Pharmacology (medical)
Abstract AUTHORS' CONCLUSIONS: Based on the aforementioned analyses, viscosupplementation is an effective treatment for OA of the knee with beneficial effects: on pain, function and patient global assessment; and at different post injection periods but especially at the 5 to 13 week post injection period. It is of note that the magnitude of the clinical effect, as expressed by the WMD and standardised mean difference (SMD) from the RevMan 4.2 output, is different for different products, comparisons, timepoints, variables and trial designs. However, there are few randomised head-to-head comparisons of different viscosupplements and readers should be cautious, therefore, in drawing conclusions regarding the relative value of different products. The clinical effect for some products, against placebo, on some variables at some timepoints is in the moderate to large effect-size range. Readers should refer to relevant tables to review specific detail given the heterogeneity in effects across the product class and some discrepancies observed between the RevMan 4.2 analyses and the original publications. Overall, the analyses performed are positive for the HA class and particularly positive for some products with respect to certain variables and timepoints, such as pain on weight bearing at 5 to 13 weeks postinjection. In general, sample-size restrictions preclude any definitive comment on the safety of the HA class of products; however, within the constraints of the trial designs employed no major safety issues were detected. In some analyses viscosupplements were comparable in efficacy to systemic forms of active intervention, with more local reactions but fewer systemic adverse events. In other analyses HA products had more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the treatment of knee OA.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Scopus Import - Archived
Version Filter Type
Citation counts: Scopus Citation Count Cited 397 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 15 Dec 2017, 16:21:21 EST